AmerisourceBergen (AB) has introduced a suite called ‘Clinical Trial Navigator’ to boost equitable and accessible community-based research opportunities in the US.

The suite aids in biopharmaceutical clinical trial recruitment specially within community-based specialty practices. 

Using the strong research community AdvanceIQ Network of AB, Clinical Trial Navigator merges oncology practices and their patients with trials using digital site selection, patient detection and enrolment tools. 

AdvanceIQ is a network of independent practices that have previously agreed to take part in research opportunities. 

Biopharmaceutical firms can enter crucial protocol criteria within the Clinical Trial Navigator suite to detect appropriate practice sites and their ideal subject populations.

Furthermore, results can be streamlined by including biomarkers or therapy regimens that subjects must have received to be eligible for a trial. 

Other filters such as one or more states, diagnosis stage, line of treatment, ECOG status, comorbidities, gender, age and race or ethnicity can also be included.

Biopharmaceutical firms will have the opportunity to network with practices that are part of AdvanceIQ.

The latest offering is anticipated to reach over 700 practices in the country and 4,700 physicians who treat 245,000 patients every month.

AmerisourceBergen Specialty Physician Services senior vice-president and president Jennifer Sherak said: “Historically, it has been difficult for biopharmaceutical companies to have a consolidated and holistic view of independent specialty practices and their patient populations, and, as a result, clinical trial enrolment and logistics in these care settings have been complex and difficult to execute. 

“With Clinical Trial Navigator, we want to break down these barriers for biopharma companies, bring more clinical trials into communities nationwide, help broaden the patient populations being considered for trials, and ultimately advance accrual time and bring therapies to market faster.”